Identification of Providencia spp. clinical isolates co-producing carbapenemases IMP-27, OXA-24, and OXA-58 in Mexico

Paola Bocanegra-Ibarias,Josefina Duran-Bedolla,Jesús Silva-Sánchez,Ulises Garza-Ramos,Alejandro Sánchez-Pérez,Elvira Garza-Gonzáles,Rayo Morfín-Otero,Humberto Barrios-Camacho,Bocanegra-Ibarias Paola,Duran-Bedolla Josefina,Silva-Sánchez Jesús,Garza-Ramos Ulises,Garza-Gonzáles Elvira,Morfín-Otero Rayo,Barrios-Camacho Humberto
DOI: https://doi.org/10.1016/j.diagmicrobio.2024.116246
IF: 2.983
2024-03-07
Diagnostic Microbiology and Infectious Disease
Abstract:Providencia rettgeri , belonging to the genus Providencia , had gained significant interest due to its increasing prevalence as a common pathogen responsible for healthcare-associated infections in hospitals. P. rettgeri isolates producing carbapenemases have been reported to reduce the efficiency of carbapenems in clinical antimicrobial therapy. However, coexistence with other resistance determinants is rarely reported. The goal of this study was the molecular characterization of carbapenemase-producing Providencia spp. clinical isolates. Among 23 Providencia spp. resistant to imipenem, 21 were positive to bla NDM-1 ; one positive to bla NDM-1 and bla OXA-58 like ; and one isolate co-producing bla IMP-27 , bla OXA-24/40 like , and bla OXA-58 like were identified. We observed a low clonal relationship, and the incompatibility groups Col3M and ColRNAI were identified in the plasmid harboring bla NDM-1 . We report for the first time a P. rettgeri strain co-producing bla IMP-27 , bla OXA-24-like , and bla OXA-58 like . The analysis of these resistance mechanisms in carbapenemase co-producing clinical isolates reflects the increased resistance.
infectious diseases,microbiology
What problem does this paper attempt to address?